30–80 Dose as in normal renal function5–29 Start at a low dose and gradually increase according to response<5 Start at a low dose and gradually increase according to response
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unlikely to be dialysed. Dose as in GFR<5 mL/min.
HD                     :Not dialysed. Dose as in GFR<5 mL/min.
HDF/high flux   :Not dialysed. Dose as in GFR<5 mL/min.
CAV/VVHD      :Unlikely to be dialysed. Dose as in GFR=5–29 mL/min.
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
Antibacterials: effects enhanced by clarithromycin and possibly trimethoprim; hypoglycaemic effect antagonised by rifampicin
Antifungals: effect possibly enhanced by itraconazole
Ciclosporin: possibly enhanced hypoglycaemic effectLipid-lowering agents: increased risk of severe hypoglycaemia with gemfibrozil – avoid concomitant use
ADMINISTRATION
Reconstition
–
Route
Oral
Rate of Administration
–
Comments
–
OTHER INFORMATION
Major route of elimination is hepatic metabolism to inactive metabolites which are excreted via the bile.